Drugs / CT-G20
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04418297 | Oct 2020 → Nov 2022 | hypertrophic cardiomyopathy | Celltrion | Terminated | No outcome recorded |
| Phase 1 | NCT03918967 | Apr 2019 → Jun 2020 | — | Celltrion | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-G20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03918967 ↗ |
| Route | Oral | “oral tablet of CT-G20 Experimental Drug” NCT03918967 ↗ |